Cardica, FDA Seek To Account For Missing PAS Port Trial Patients
This article was originally published in The Gray Sheet
Executive Summary
FDA should shift the burden of evidence on anastomotic connector devices to postmarket trials because of difficulties in obtaining angiographic follow-up data in pivotal studies, Cardica maintains